CALQUENCE Plus Obinutuzumab Demonstrated Sustained Survival Benefit in 1st-line Chronic Lymphocytic Leukemia with 90% of Patients Surviving Five Years in ELEVATE-TN Trial
CALQUENCE also maintained efficacy and a sustained safety profile at four years for previously treated patients in ASCEND trial WILMINGTON, Del.--(BUSINESS WIRE)--Updated results from the ELEVATE-TN Phase III trial showed ...